294 results about "Vein thrombosis" patented technology

A temporary inferior vena cava filter including a guidewire and a doublet cage filter distally located on the guidewire. The doublet cage filter has a proximal cage filter and a distal cage filter, both of resilient and biased toward their expanded or deployed state. The proximal and distal cage filters may be collapsed by actuation, preferably with a sheath. A method of protecting from pulmonary embolism during treatment of a deep vein thrombosis is disclosed. The doublet cage provides stability when deployed in the inferior vena cava, is readily retrieved and readily manufactured. A method of manufacturing the doublet cage filter assembly is also disclosed and involves a nitinol tube with plural cuts to form struts which are heat treated in an expanded state.

A system for providing prophylaxis against thrombosis comprises in combination a vehicle and a plurality of inflatable compression sleeves. The vehicle has a pneumatic pressure source for supplying a predetermined flow of pneumatic fluid to a plurality of passenger positions. The pneumatic pressure source has a plurality of leads, which extend to a connection port located in each of the passenger positions. Each of the inflatable compression sleeves has a plurality of inflatable chambers therein. The sleeves are constructed to be engaged to a connection port, thereby providing fluid communication between the pneumatic pressure source and the plurality of chambers. The sleeves may be worn by a passenger to help prevent the occurrence of deep vein thrombosis. Individual sleeves comprise at least two inflatable chambers wherein a second inflatable chamber is subsequent to the inflation of a first inflatable chamber.

An electromagnetic stimulation device which is comprised of a plurality of overlapping coils which are able to be independently energized in a predetermined sequence such that each coil will generate its own independent electromagnetic field and significantly increase the adjacent field. The coils are co-planar and are disposed in an ergonomic body wrap, which is properly marked to permit an unskilled patient to locate the body wrap, on a particular part of the body, of the patient so that the stimulation coils will maximize the electromagnetic stimulation on the selected nerves, muscles, and/or body tissues near the treated area. The device can be used to treat medical conditions including: muscular atrophy, neuropathic bladder and bowel, musculoskeletal pain, arthritis, as well as possible future applications in the prevention of deep vein thrombosis and weight reduction.

This invention provides a mechanical lower extremity manipulation device to increase venous blood flow in lower extremities for the prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), lower extremity edema, and other associated or related conditions. Foot plates pivoting on a base plate can be powered to provide a reciprocating action to the feet of a reclining patient. Straps can hold the patient's legs against the base plate so that the reciprocating action results in alternate planar flexion and dorsal flexion of the foot without movement of the leg in general. The resulting elongation and retraction of lower leg muscles can improve venous blood flow to reduce the risk of pathologies, such as DVT.

The invention describes a method to automatically controlling, single channel Neuromuscular Electrical Stimulation (NMES) of the plantar muscle, in response to the sensing of motion of the foot or leg: to reduce accommodation of the stimulated plantar muscle and attendant reduction of contractions, which when undiminished increase blood flow for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE); to turn off the stimulation during walking or running to prevent slips or falls; and to reduce power consumption of the unit that provides the stimulation.

A vascular filter system and method are disclosed. In one embodiment, the filter system comprises a dispensing needle releasably attached to a filter dispenser which stores a length of filter wire. The filter wire dispenser has a guide tube which guides the filter wire into the needle and then into a vein during surgical implantation. The filter wire is configured to coil into a predetermined shape as it is deployed from the needle. The shape of the filter wire captures blood clots in the blood stream. Once the filter wire is deployed, the needle may be removed and a portion of the filter wire may be left protruding from the patient's skin surface to allow the filter wire to be secured by a fixation device. A syringe may be used to draw blood to confirm that the needle is properly positioned within a vein before the filter wire is deployed.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out venous thromboembolic disease, pulmonary embolism, and/or deep vein thrombosis, and for risk stratification in such conditions.

A connector assembly includes first and second mating connectors that can be joined to make a fluid connection. The connectors are constructed to discriminate improper connectors so that no fluid tight connection can be formed with improper connectors. The connector assembly can be used with a system for compression therapy to prevent deep vein thrombosis.

Aiming at the conditions that heparin has severe bleeding side effects in clinical practice and clinical application thereof is restricted, the invention discloses a technique for producing ultra-low molecular heparin sodium (calcium). The technique comprises the following steps of: taking heparin sodium solution, adding sodium nitrite solution for cracking; adjusting the lysis buffer by using alkaline; absorbing impurities by using an anion-exchange column; washing for obtaining ultra-low molecular heparin calcium; carrying out filtration by using an ultrafiltration membrane and obtaining a precipitate by using alcohol; and after desalting, dehydration, re-precipitation, cooling and drying, obtaining a finished product of ultra-low molecular heparin calcium. The product has better and safer antithrombotic effect under low level of anticoagulation, and can be widely used for preventing and treating diseases such as deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and the like.

A connector apparatus includes first and second mating connectors that can be joined to make a fluid connection. The connectors are constructed to discriminate improper connectors so that no fluid tight connection can be formed with improper connectors. The connector apparatus can be used with a system for compression therapy to prevent deep vein thrombosis.

A device for monitoring the activity of a user to prevent deep vein thrombosis when working. The device comprises a carrier (20) for positioning on or adjacent a user, a motion sensor (10) mounted on the carrier (20) and adapted to detect the user performing a predefined motion, processor adapted to filter the motion detected to remove background motion not attributable to the desired exercise and to reset a timer (12) when the predefined motion is detected. An alarm (14) is operated by the processor should the time period elapse without the exercise pattern being detected. The components are all contained in the carrier (20) which is preferably a small container that can be attached to a user's trousers or around the limb of a wearer. Failure to undertake the required motion will cause the alarm (14) to be activated, thus notifying the wearer of the omission.

Portable devices and methods for preventing deep vein thrombosis (DVT) by assuring that the ankle is flexed and extended sufficiently to promote blood flow in the lower leg are disclosed. The device includes an actuator with a free movement mode that allows a patient to move freely between activations or to initiate movement to delay a next automatic activation.

A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and/or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

Disclosed herein are systems and methods to remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

An apparatus for enhancing blood flow through a limb of a subject includes a compression sleeve extendable around the subject's limb and having a plurality of compressors situated next to one another along the sleeve. In use, the compressors compress the limb in sequence to move blood within the limb from one end of the sleeve to the other. In particular, as a said compressor begins to compress the limb, the compressor preceding it in sequence already compresses the limb, and the next preceding compressor in sequence ceases to compress the limb.

This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

There is provided a continuous passive motion (CPM) machine with integrated mechanical deep vein thrombosis (DVT) prophylaxis for providing simultaneous CPM therapy and DVT prophylactic therapy to a human patient. The passive motion machine may include a base, at least one motor, one or more hinged frame rails, one or more support or suspension structures and a roller assembly. The hinged frame rails are driven to impart CPM to a patient's limb. The roller assembly can be a single roller, a multiple roller unit, or a belt and roller apparatus. A motor and connecting drive rotates the roller assembly. The roller assembly engages the patient's limb and the one or more rollers apply a mechanical DVT prophylaxis therapy to the limb, reducing the risk of blood clotting.

A non-invasive apparatus for rehabilitating a joint, limb, and muscles of a patient recovering from surgery on the joint, includes a continuous passive motion device having at least one support member for supporting the limb, at least one hinge coupled to the at least one support member, and at least one actuator for providing reciprocating motion of the at least one support member about the at least one hinge, a plurality of electrodes transmitting at least four modalities chosen from a group consisting of functional electrical stimulation (FES), transcutaneous electrical nerve stimulation (TENS), temperature therapy stimulation, deep vein thrombosis (DVT) prophylactic stimulation, venous blood flow monitoring, and pain monitoring, and a control unit controlling the at least one actuator and the plurality of electrodes according to a coordinated sequence of the reciprocating motion and transmission of the at least four modalities.

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.